Keytruda combo gains FDA approval in first-line RCC

FDA approved a BLA for Keytruda pembrolizumab in combination with Inlyta axitinib as a first-line therapy for advanced renal cell carcinoma. The decision, which arrived

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE